Study of XTX501 for advanced lung cancer and other solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called XTX501 for people with advanced non-small cell lung cancer (NSCLC) or other solid tumors. The drug may help the immune system fight cancer, and the study aims to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have measurable cancer (tumors that can be seen on scans).
- You must be able to take care of yourself (ECOG performance status 0 or 1).
- Your organs (like liver, kidneys, and bone marrow) must be working well enough.
- If you have lung cancer, it must be non-small cell lung cancer that has spread, and you must have had a previous immunotherapy (PD-1/PD-L1 inhibitor) that helped for at least 6 months.
- You cannot have certain genetic changes (like EGFR, ALK, ROS1, RET, MET, HER-2, NTRK) in your tumor.
- You must not have had prior treatment with IL-2, significant lung or heart disease, or active brain metastases.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
This trial tests a new medicine, STX-241, for people with a specific type of advanced lung cancer (NSCLC) that has stopped responding to current targeted therapies. The goal is to see if this new drug can help shrink or control the cancer.
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.